Trade Names:Cartrol- Tablets 2.5 mg- Tablets 5 mg
Trade Names:Carteolol Hydrochloride- Solution, ophthalmic 1%
Blocks beta-receptors, primarily affecting cardiovascular system (eg, decreases heart rate, cardiac contractility, BP) and lungs (promotes bronchospasm). Ophthalmic use reduces IOP, probably by decreasing aqueous production.
Well absorbed. T max is 1 to 3 h. Bioavailability is about 85%.
23% to 30% protein bound.
Metabolized to 8-hydroxycarteolol (active) and glucuronide conjugates.
The t ½ is about 6 h (carteolol) and about 8 to 12 h (8-hydroxycarteolol). About 50% to 70% is excreted unchanged by the kidneys.
The t ½ may be prolonged and elimination decreased. Dosage adjustment may be needed.
Management of hypertension. Ophthalmic preparation for control of intraocular hypertension and lowering of IOP in chronic open-angle glaucoma.
Treatment of angina.
Hypersensitivity to beta-blockers; persistently severe bradycardia; greater than first-degree AV block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; bronchial asthma or bronchospasm, including severe chronic obstructive pulmonary disease (COPD).
PO 2.5 to 10 mg every day.Ophthalmic use
1 drop twice daily in affected eye(s). Consider concomitant therapy if IOP is not at satisfactory level.
For ophthalmic solution, pull out lower lid to create pocket, administer drop without touching eye, release lower lid, close eye, and apply gentle pressure on inner canthus of eye to avoid systemic absorption.
Store at room temperature.
May enhance or reverse antihypertensive effect; may cause potentially life-threatening increases in BP, especially on simultaneous discontinuation of both drugs.Epinephrine
May cause initial hypertensive episode followed by bradycardia.Ergot derivatives
May cause peripheral ischemia with cold extremities. Peripheral gangrene possible.NSAIDs
May impair antihypertensive effect.Prazosin
May increase orthostatic hypotension.Systemic beta-blocker
When coadministered with ophthalmic carteolol hydrochloride solution, may cause additive effects and toxicity.Theophyllines
May reduce elimination of theophylline. May cause pharmacologic antagonism, reducing effects of one or both drugs.Verapamil
May increase effects of both drugs.
None well documented.
Hypotension; bradycardia; CHF; cold extremities; first-, second-, or third-degree atrioventricular block; arrhythmias; syncope.
Insomnia; fatigue; dizziness; depression; lethargy; drowsiness; forgetfulness; headache.
Rash; hives; alopecia.
Dry eyes; blurred vision; tinnitus; slurred speech; dry mouth; sore throat. Eye discomfort or stinging; tearing; keratitis; drooping eyelids; visual disturbances; diplopia; ptosis (ophthalmic use).
Nausea; vomiting; diarrhea; constipation.
Impotence; painful, difficult, or frequent urination.
Agranulocytosis; thrombocytopenic purpura.
Hyperglycemia; hypoglycemia; unstable diabetes mellitus; hypercholesterolemia; hyperlipidemia; increased LDH.
Bronchospasm; shortness of breath; wheezing.
Weight changes; fever; facial swelling; cramps; muscle weakness. Antinuclear antibodies may develop.
Monitor BP and pulse frequently when starting oral medication or when dosage is changed.IOP
Perform measurements of IOP on regular basis to assess therapeutic effect of ophthalmic medication.
Category C .
Excreted in breast milk.
Safety and efficacy not established.
Requires dosage adjustment.
Requires dosage adjustment.
Discontinue therapy gradually, over about 2 wk, with careful observation of patient and limited physical activity.
Administer cautiously in patients with CHF treated with digitalis and diuretics.
Drug may mask signs and symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia.
Drug may precipitate or aggravate symptoms of arterial insufficiency.
May mask clinical signs of developing or continuing hyperthyroidism (eg, tachycardia). Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm.
Bradycardia, cardiac failure, hypotension, bronchospasm, hypoglycemia.
Copyright © 2009 Wolters Kluwer Health.